全文获取类型
收费全文 | 128篇 |
免费 | 12篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 3篇 |
基础医学 | 3篇 |
临床医学 | 22篇 |
神经病学 | 42篇 |
外科学 | 4篇 |
综合类 | 3篇 |
预防医学 | 1篇 |
药学 | 63篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 1篇 |
2014年 | 6篇 |
2013年 | 5篇 |
2012年 | 4篇 |
2011年 | 5篇 |
2010年 | 10篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 6篇 |
2006年 | 7篇 |
2005年 | 5篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 5篇 |
2001年 | 8篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 3篇 |
1997年 | 6篇 |
1996年 | 6篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有142条查询结果,搜索用时 15 毫秒
11.
目的:探讨氟伏沙明合并奥氮平对有精神病性症状抑郁症的临床疗效及安全性。方法:将115例患者随机分为氟伏沙明联合奥氮平组、氟伏沙明联合舒必利组,疗程8周。采用汉密尔顿抑郁量表(HAMD)、简明精神病评定量表(BPRS)观察疗效,用治疗中出现的症状量表(TESS)评定不良反应。结果:治疗8周两组BPRS、HAMD总分及各因子分均较治疗前显著降低(P均〈0.01);氟伏沙明联合奥氮平组起效较快,疗效亦较好。两组不良反应接近。结论:氟伏沙明联合奥氮平治疗有精神病性症状的抑郁症疗效肯定,安全性高。 相似文献
12.
Teichert M Visser LE Uitterlinden AG Hofman A Buhre PJ Straus S De Smet PA Stricker BH 《British journal of clinical pharmacology》2011,72(5):798-805
AIM
The aim of this study was to investigate the effects of co-medication with selective serotonin re-uptake inhibitors (SSRIs) on overanticoagulation during acenocoumarol maintenance treatment.METHODS
All subjects from The Rotterdam Study who received acenocoumarol maintenance treatment between April 1 1991 and September 9 2009 were followed for the event of an international normalized ratio (INR) ≥6, until death, end of treatment or end of the study period. With the Andersen-Gill extension of the Cox proportional hazards model, risks for repeated events of overanticoagulation in relation to concomitant SSRI use were calculated.RESULTS
The risk for overanticoagulation during acenocoumarol maintenance treatment was increased in combination with fluvoxamine (HR 2.63, 95% CI 1.49, 4.66) and venlafaxine (HR 2.19, 95% CI 1.21, 3.99). There was no increase in risk for the other SSRIs, but numbers of exposed cases were low for all SSRIs except paroxetine.CONCLUSION
Fluvoxamine and venlafaxine were associated with a more than double risk of INR values ≥6 in acenocoumarol treated subjects. 相似文献13.
Vlase L Popa A Neag M Muntean D Achim M Leucuţa SE 《Clinical and experimental pharmacology & physiology》2012,39(1):9-12
1. Our objective was to evaluate a possible pharmacokinetic interaction between zolpidem and fluvoxamine in healthy volunteers. 2. The study consisted of two periods: Period 1 (reference), when each volunteer received a single dose of 5 mg zolpidem; and Period 2 (test), when each volunteer received a single dose of 5 mg zolpidem and 100 mg fluvoxamine. Between the two periods, the subjects were treated for 6 days with a single daily dose of 100 mg fluvoxamine. 3. Pharmacokinetic parameters of zolpidem given in each treatment period were calculated using non-compartmental analysis and the data from two periods were compared to determine statistically significant differences. 4. In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 56.4 ± 25.6 ng/mL (zolpidem alone) and 67.3 ± 25.8 ng/mL (zolpidem after pretreatment with fluvoxamine). The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively. The half-life of zolpidem was 2.24 ± 0.81 h when given alone and 4.99 ± 2.92 h after pretreatment with fluvoxamine. 5. Fluvoxamine interacts with zolpidem in healthy volunteers and increases its exposure by approximately 150%. The experimental data showed the pharmacokinetic interaction between zolpidem and fluvoxamine, and suggest that the observed interaction might be clinically significant, but its relevance has to be confirmed. 相似文献
14.
Chertkow Y Weinreb O Youdim MB Silver H 《Journal of neural transmission (Vienna, Austria : 1996)》2007,114(11):1443-1454
Summary Treating primary ‘negative symptoms’ of schizophrenia with a combination of a typical antipsychotic and a selective serotonin
reuptake inhibitor, is more effective than with antipsychotic alone and is similar to the effect of the atypical antipsychotic,
clozapine. The mechanism of this treatment combination is unknown and may involve changes in dopaminergic and serotonin systems.
We studied dopamine and serotonin metabolism in different rat brain areas at 1.5 and 24 h after the last dosage of chronic
treatment (30 days), with haloperidol plus fluvoxamine, each drug alone, and clozapine. Haloperidol-fluvoxamine combination,
haloperidol, and clozapine treatments increased striatal and frontal cortex dopamine turnover and reduced striatal tyrosine
hydroxylase activity at 1.5 h. At 24 h both dopamine turnover and tyrosine hydroxylase activity were reduced. Thus, in chronically
treated animals, release of striatal dopamine increases following a drug pulse and returns to baseline by 24 h. Serotonin
and 5-hydroxyindoleacetic acid concentrations were decreased at 1.5 h in haloperidol-fluvoxamine and clozapine groups and
returned to normal levels by 24 h. A limited behavioral assessment showed that treatment with haloperidol plus fluvoxamine
reduced motor activity compared to haloperidol, and increased sniffing compared to haloperidol, fluvoxamine and clozapine.
These findings indicate that combining antipsychotic with SSRI results in specific changes in dopaminergic and serotonergic
systems and in behavior. The possibility that these may be relevant to the mechanism underlying the clinical effectiveness
of augmentation treatment warrant further study.
An erratum to this article is available at . 相似文献
15.
Naito S Sato K Yoshida K Higuchi H Takahashi H Kamata M Ito K Ohkubo T Shimizu T 《Psychiatry and clinical neurosciences》2007,61(4):421-427
Gender differences in the treatment response to fluvoxamine (selective serotonin re-uptake inhibitor) and milnacipran (serotonin/norepinephrine re-uptake inhibitor) were investigated in Japanese major depressive patients. A total of 125 Japanese patients was included in the present study. Sixty-six patients received fluvoxamine treatment. The daily dose was 50 mg/day for the first week and increased to 100 mg after 1 week, up to 200 mg after another week. Fifty-nine patients were given milnacipran. The daily dose was 50 mg/day for the first week, and up to 100 mg/day thereafter. Patients were divided into three groups: younger women (<44 years of age), older women (> or =44 years of age) and men. Depressive symptoms were evaluated using the Montgomery and Asberg Depression Rating Scale (MADRS) before treatment and at 1, 2, 4 and 6 weeks after the beginning of the study. In comparison with other groups, younger women treated with fluvoxamine demonstrated a significant difference in the time course of MADRS score change. However, these gender/age-related differences of antidepressant response were not observed in the patients treated with milnacipran. The results suggest that fluvoxamine is more effective in younger female patients than older female patients and male patients, while milnacipran is generally effective irrespective of gender or age. 相似文献
16.
John Price Patrick Waller Susan Wood Angus MacKay 《Pharmacoepidemiology and drug safety》1992,1(3):111-117
This review examines data on the safety of two 5-HT reuptake inhibitors, fluoxetine and fluvoxamine. A comparison of the spontaneous reports of suspected adverse reactions to each drug sent to the UK Committee on Safety of Medicines has been made. This does not reveal important differences in their safety profile. 相似文献
17.
Tomohiro Nakao Akiko Nakagawa Takashi Yoshiura Eriko Nakatani Maiko Nabeyama Chika Yoshizato Akiko Kudoh Kyoko Tada Kazuko Yoshioka Midori Kawamoto Osamu Togao Shigenobu Kanba 《Neuropsychopharmacology》2005,57(8):901-910
BACKGROUND: Functional neuroimaging studies have implicated hyperactivity of the frontal cortex in obsessive-compulsive disorder (OCD); however, relationships between abnormal brain activity, clinical improvement, and neuropsychological function have not been clarified in OCD. To clarify the pathophysiology of this disorder, regional changes in brain function were examined during administration of cognitive and symptom provocation tasks in patients with OCD before and after treatment. METHODS: Ten outpatients with OCD participated in the study. Functional magnetic resonance imaging (fMRI) was performed before and after treatment. Stroop and symptom provocation tasks were administered during fMRI. Each patient was randomly allocated to receive either pharmacotherapy with fluvoxamine 200 mg/day (n = 4) or behavior therapy (n = 6) for 12 weeks. RESULTS: After 12-week treatment, mean (+/- SD) total score on the Yale-Brown Obsessive-Compulsive Scale decreased from 29.00 +/- 3.59 to 14.60 +/- 9.22, representing symptomatic improvement from moderate to mild. After symptom improvement, symptom provocation-related activation in the orbitofrontal, dorsolateral-prefrontal, and anterior cingulate cortices decreased. Conversely, Stroop task-related activation in the parietal cortex and cerebellum increased. CONCLUSIONS: After improvement of OCD with either fluvoxamine or behavioral therapy, hyperactivation of the frontal lobe related to a symptom-provocative state decreases, and posterior brain activity related to action-monitoring function increases. 相似文献
18.
19.
B. Saletu J. Grünberger P. Anderer L. Linzmayer G. Zyhlarz 《Journal of neural transmission (Vienna, Austria : 1996)》1996,103(1-2):191-216
Summary In a double-blind, placebo-controlled study, the encephalotropic and psychotropic effects of tianeptine (TIA) — a new tricyclic antidepressant, enhancing serotonin reuptake — were investigated as compared with the serotonin reuptake inhibiting antidepressant, fluvoxamine (FLU), utilizing EEG mapping, psychometric and psychophysiological measures. 16 healthy volunteers (8 males, 8 females) aged 21–35 (man 27) years received randomized and at weekly intervals single oral doses of placebo, 12.5 and 25 mg TIA and 50mg FLU. EEG recordings, psychometric and psychophysiological tests and evaluation of pulse, blood pressure and side effects were carried out at 0,2,4,6 and 8 hours; blood sampling, in addition, at hour 1.TIA plasma levels rose fast to peaks at 1–2 hours and declined rapidly as well, while the MC5 metabolite peaked in the 4th hour and declined more slowly. EEG mapping demonstrated that both TIA and FLU induced significant changes in brain function between the 1st and 8th hour, which, however, differed in their time course. 12.5 mg TIA exhibited, as compared with placebo, slight activating properties in the EEG (decrease of delta and theta, increase of alpha and beta, acceleration of the centroid), parallelled by thymopsychic improvement (mood elevation). 25 mg TIA showed EEG activation up to the 4th hour, later EEG sedation, accompanied by an initial thymopsychic improvement and differential changes thereafter (improved mood, decreased vigility), with the noopsyche improving at all times (attention, Pauli test). 50mg FLU induced initially sedation and thereafter activation, accompanied by thymopsychic deterioration and subsequent improvement, the latter also being observed in the noopsyche (attention, memory). In pupillary and skin conductance measures, generally a slight activation occurred after placebo, which was attenuated by 25 mg TIA. Correlation maps between plasma levels and EEG changes demonstrated: the higher the TIA plasma levels, the more absolute and relative beta power, the less alpha power and the faster the centroid of the total power spectrum, reflecting CNS-activation. Topographically, the correlations were mostly seen over both fronto-temporal regions. In the latter, dominant frequency signalled desactivation in the right and activation in the left hemiphere after both antidepressants, which thereby induced changes in brain function opposite to those observed in depression. Both drugs were well tolerated. 相似文献
20.
Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity
下载免费PDF全文
![点击此处可从《British journal of clinical pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Chen YC Gotzkowsky SK Nafziger AN Kulawy RW Rocci ML Bertino JS Kashuba AD 《British journal of clinical pharmacology》2006,62(2):187-195
AIMS: A non-invasive proposed method for measuring CYP3A activity is the urinary 6beta-hydroxycortisol:cortisol ratio. This ratio has been used as an indicator of CYP3A induction and inhibition, with mixed results. This investigation evaluated the relationship between a validated, biomarker, intravenous midazolam clearance and the urinary cortisol ratio under constitutive conditions and with the influence of a moderate CYP3A inhibitor. METHODS: This was a sequential, cross-over study design. Intravenous midazolam 0.025 mg kg(-1) was administered to 10 male and 10 female subjects once every 14 days for 4 months. Fluvoxamine 150 mg day(-1) was given to all subjects during the last two visits. Total body clearance of midazolam and urinary 6beta-hydroxycortisol:cortisol molar ratio were used as biomarkers of hepatic CYP3A activity. RESULTS: No significant correlations were found between these two markers (r(2) < 0.5, P > 0.05). Larger interindividual and intra-individual variability in CYP3A activity was observed in 6beta-hydroxycortisol:cortisol ratios compared with midazolam clearances. With fluvoxamine therapy, midazolam clearance values decreased approximately 1.5-fold and cortisol ratios decreased approximately 1.9-fold. CONCLUSIONS: The high intra-individual variability of the urinary cortisol ratio, compared with midazolam, makes this a suboptimal CYP3A phenotyping tool. 相似文献